{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:18:35Z","timestamp":1794622715173,"version":"4.9.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,28]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune thrombotic thrombocytopenic purpura (iTTP) is a chronically relapsing disorder caused by autoantibody-mediated deficiency of ADAMTS13. Rituximab is frequently administered to prevent relapses, but whether the durability of rituximab effect is maintained with subsequent treatment courses has not been studied. Using the United States Thrombotic Microangiopathy Consortium (USTMA) retrospective iTTP registry, we evaluated clinical relapse-free survival (RFS) with subsequent courses of rituximab treatment in multiply relapsing patients. Separately, we evaluated overall RFS (composite of time to clinical relapse, ADAMTS13 relapse, or preemptive rituximab) in a prospective iTTP cohort from the Johns Hopkins University and the University of Minnesota. In the USTMA registry, median clinical RFS was shorter after the second or subsequent rituximab-treated episode than the first (2.1 vs 6.0 years; P\u00a0=\u00a0.04). White patients\u2019 clinical relapse risk after the second and subsequent rituximab courses was not significantly different compared with the first (hazard ratio [HR], 1.86; 95% confidence interval [CI], 0.22-15.80; P\u00a0=\u00a0.57), whereas for Black patients, clinical relapse risk was significantly higher after the second or subsequent courses (HR, 2.82; 95%\u00a0CI, 1.52-5.24; P\u00a0=\u00a0.001). In the prospective cohort, overall RFS progressively shortened after each episode of rituximab treatment with the first episode having the longest RFS (2.8 years; interquartile range, 2.0-6.0) and this loss of response durability was most pronounced in Black patients. The durability of rituximab\u2019s effect declines with subsequent treatments, which is more pronounced in Black patients, who may benefit from closer monitoring and alternative immunomodulatory approaches such as maintenance rituximab and consideration of other agents.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013313","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T22:30:32Z","timestamp":1733265032000},"page":"417-424","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9624-4293","authenticated-orcid":false,"given":"Ayotola","family":"Fatola","sequence":"first","affiliation":[{"name":"1Department of Medicine, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7449-3993","authenticated-orcid":false,"given":"Michael D.","family":"Evans","sequence":"additional","affiliation":[{"name":"2Clinical and Translational Science Institute, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Brown","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Davis","sequence":"additional","affiliation":[{"name":"3Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Johnson","sequence":"additional","affiliation":[{"name":"4Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana G.","family":"Antun","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Farland","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Wake Forest University, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Woods","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Wake Forest University, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-8639","authenticated-orcid":false,"given":"Ara","family":"Metjian","sequence":"additional","affiliation":[{"name":"7Department of Medicine, University of Colorado, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara A.","family":"Park","sequence":"additional","affiliation":[{"name":"8Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustaaf","family":"de Ridder","sequence":"additional","affiliation":[{"name":"8Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC"},{"name":"9Department of Pathology, Geisinger Medical Center, Danville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"Gibson","sequence":"additional","affiliation":[{"name":"8Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC"},{"name":"10Gulf Regional Pathologists, Mobile, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6672-3082","authenticated-orcid":false,"given":"Raj S.","family":"Kasthuri","sequence":"additional","affiliation":[{"name":"11Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darla K.","family":"Liles","sequence":"additional","affiliation":[{"name":"12Department of Medicine, East Carolina University, Greenville, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Eubanks","sequence":"additional","affiliation":[{"name":"12Department of Medicine, East Carolina University, Greenville, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Akwaa","sequence":"additional","affiliation":[{"name":"13Department of Medicine, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Clover","sequence":"additional","affiliation":[{"name":"14Department of Hematology and Oncology, St. Charles Healthcare, Bend, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1171-0548","authenticated-orcid":false,"given":"Lisa Baumann","family":"Kreuziger","sequence":"additional","affiliation":[{"name":"15Versiti Blood Center of Wisconsin, Milwaukee, WI"},{"name":"16Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Evan","family":"Sadler","sequence":"additional","affiliation":[{"name":"17Department of Medicine, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7225-8228","authenticated-orcid":false,"given":"Meera","family":"Sridharan","sequence":"additional","affiliation":[{"name":"18Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"18Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7340-475X","authenticated-orcid":false,"given":"Keith R.","family":"McCrae","sequence":"additional","affiliation":[{"name":"19Department of Medicine, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh Vardhan","family":"Upreti","sequence":"additional","affiliation":[{"name":"20Department of Medicine, The University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-3387","authenticated-orcid":false,"given":"Ming Y.","family":"Lim","sequence":"additional","affiliation":[{"name":"21Department of Medicine, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole K.","family":"Kocher","sequence":"additional","affiliation":[{"name":"22Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Gangaraju","sequence":"additional","affiliation":[{"name":"23Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1680-5295","authenticated-orcid":false,"given":"X. Long","family":"Zheng","sequence":"additional","affiliation":[{"name":"4Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN"},{"name":"22Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, MO"},{"name":"24Institute of Reproductive Medicine and Developmental Sciences, University of Kansas Medical Center, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9835-957X","authenticated-orcid":false,"given":"Jay S.","family":"Raval","sequence":"additional","affiliation":[{"name":"25Department of Pathology, University of New Mexico, Albuquerque, NM"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Masias","sequence":"additional","affiliation":[{"name":"26Department of Hematology and Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8977-6910","authenticated-orcid":false,"given":"Spero R.","family":"Cataland","sequence":"additional","affiliation":[{"name":"27Department of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4294-3069","authenticated-orcid":false,"given":"Marshall","family":"Mazepa","sequence":"additional","affiliation":[{"name":"3Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"issue":"21","key":"2025012813561003700_bib1","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2025012813561003700_bib2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025012813561003700_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2141.1996.d01-1800.x","article-title":"Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group","volume":"94","author":"Rock","year":"1996","journal-title":"Br J Haematol"},{"issue":"3","key":"2025012813561003700_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.2022017023","article-title":"Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy","volume":"141","author":"Doyle","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025012813561003700_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-138-2-200301210-00011","article-title":"Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab","volume":"138","author":"Zheng","year":"2003","journal-title":"Ann Intern Med"},{"key":"2025012813561003700_bib7","doi-asserted-by":"crossref","first-page":"bcr2016215491","DOI":"10.1136\/bcr-2016-215491","article-title":"Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura","volume":"2016","author":"Acedillo","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"12","key":"2025012813561003700_bib8","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/ajh.24559","article-title":"Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: results of a phase II, multicenter noncomparative study","volume":"91","author":"Benhamou","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"2025012813561003700_bib9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.13408","article-title":"A\u00a0phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed\/refractory thrombotic thrombocytopenic purpura treated with rituximab","volume":"170","author":"Clark","year":"2015","journal-title":"Br J Haematol"},{"issue":"7","key":"2025012813561003700_bib10","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A\u00a0phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2025012813561003700_bib11","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Page","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2025012813561003700_bib12","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"20","key":"2025012813561003700_bib13","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"issue":"15","key":"2025012813561003700_bib14","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"issue":"9","key":"2025012813561003700_bib15","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/bloodadvances.2019031039","article-title":"Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura","volume":"3","author":"Sun","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"2025012813561003700_bib4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood.2022016640","article-title":"Race, rituximab, and relapse in TTP","volume":"140","author":"Chaturvedi","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2025012813561003700_bib16","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2025012813561003700_bib17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2141.2008.07107.x","article-title":"Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse","volume":"141","author":"Jin","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"2025012813561003700_bib18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"issue":"14","key":"2025012813561003700_bib19","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an International Working Group Consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2025012813561003700_bib20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0021-9681(82)90058-3","article-title":"Adjusted survival curve estimation using covariates","volume":"35","author":"Makuch","year":"1982","journal-title":"J\u00a0Chronic Dis"},{"key":"2025012813561003700_bib21","article-title":"Coxme: mixed effects cox models","author":"Therneau","year":"2022","journal-title":"R package"},{"issue":"3","key":"2025012813561003700_bib22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2025012813561003700_bib23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.transci.2010.09.018","article-title":"Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study","volume":"43","author":"Rubia","year":"2010","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"2025012813561003700_bib24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2025012813561003700_bib25","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1182\/bloodadvances.2020004169","article-title":"Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission","volume":"6","author":"Sukumar","year":"2022","journal-title":"Blood Adv"},{"issue":"13","key":"2025012813561003700_bib26","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2025012813561003700_bib27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2025012813561003700_bib28","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/bloodadvances.2021005124","article-title":"Daratumumab for immune thrombotic thrombocytopenic purpura","volume":"6","author":"van den Berg","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"2025012813561003700_bib29","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2014-04-561142","article-title":"The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs","volume":"124","author":"Schaller","year":"2014","journal-title":"Blood"},{"issue":"589","key":"2025012813561003700_bib30","doi-asserted-by":"crossref","first-page":"eabc3961","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"2025012813561003700_bib31","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B\u00a0cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mahevas","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2025012813561003700_bib32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-065X.2010.00945.x","article-title":"B-cell targeted therapies in human autoimmune diseases: an updated perspective","volume":"237","author":"Townsend","year":"2010","journal-title":"Immunol Rev"},{"issue":"4","key":"2025012813561003700_bib33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2025012813561003700_bib34","doi-asserted-by":"crossref","first-page":"103830","DOI":"10.1016\/j.msard.2022.103830","article-title":"Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases","volume":"63","author":"Saidenberg","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"2025012813561003700_bib35","doi-asserted-by":"crossref","first-page":"fcad218","DOI":"10.1093\/braincomms\/fcad218","article-title":"Neuron-binding antibody responses are associated with Black ethnicity in multiple sclerosis during natalizumab treatment","volume":"5","author":"Telesford","year":"2023","journal-title":"Brain Commun"},{"key":"2025012813561003700_bib36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1479-5876-10-113","article-title":"Racial differences in B cell receptor signaling pathway activation","volume":"10","author":"Longo","year":"2012","journal-title":"J\u00a0Transl Med"},{"issue":"12","key":"2025012813561003700_bib37","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1002\/art.30598","article-title":"B\u00a0lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels","volume":"63","author":"Ritterhouse","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2025012813561003700_bib38","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jaci.2012.04.047","article-title":"Genetic variation in B cell-activating factor of the TNF family (BAFF) and asthma exacerbations among African American subjects","volume":"130","author":"Kumar","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"2025012813561003700_bib39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.bbi.2020.07.017","article-title":"Discrimination and systemic inflammation: a critical review and synthesis","volume":"89","author":"Cuevas","year":"2020","journal-title":"Brain Behav Immun"},{"issue":"1-2","key":"2025012813561003700_bib40","first-page":"89","article-title":"Allostatic load burden and racial disparities in mortality","volume":"104","author":"Duru","year":"2012","journal-title":"J\u00a0Natl Med Assoc"},{"issue":"1","key":"2025012813561003700_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2114\/jpa2.25.133","article-title":"The detrimental effects of allostasis: allostatic load as a measure of cumulative stress","volume":"25","author":"Stewart","year":"2006","journal-title":"J\u00a0Physiol Anthropol"},{"issue":"8","key":"2025012813561003700_bib42","first-page":"1434","article-title":"Racial discrimination, disease activity, and organ damage: the Black women's experiences living with lupus (BeWELL) study","volume":"188","author":"Chae","year":"2019","journal-title":"Am J Epidemiol"},{"issue":"6","key":"2025012813561003700_bib43","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10865-022-00357-8","article-title":"Racial\/ethnic variations in inflammatory markers: exploring the role of sleep duration and sleep efficiency","volume":"45","author":"Farmer","year":"2022","journal-title":"J\u00a0Behav Med"},{"issue":"2","key":"2025012813561003700_bib44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ejh.13886","article-title":"Preemptive cyclosporin A in immune-mediated thrombotic thrombocytopenic purpura","volume":"110","author":"Comparon","year":"2023","journal-title":"Eur J Haematol"},{"issue":"10320","key":"2025012813561003700_bib45","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"2025012813561003700_bib46","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/14712598.2023.2274912","article-title":"Antibody based therapeutics for autoimmune hemolytic anemia","volume":"23","author":"Cavallaro","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"10413","key":"2025012813561003700_bib47","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"2025012813561003700_bib48","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"2025012813561003700_bib49","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1537-2995.2009.02528.x","article-title":"Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: clinical outcomes and risk factors for relapse","volume":"50","author":"Zhan","year":"2010","journal-title":"Transfusion"},{"issue":"5","key":"2025012813561003700_bib50","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/blood.2021014514","article-title":"How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge","volume":"140","author":"Akwaa","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/2\/417\/2352229\/blooda_adv-2024-013313-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/2\/417\/2352229\/blooda_adv-2024-013313-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T13:56:31Z","timestamp":1738072591000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/2\/417\/534299\/Relapse-free-survival-is-progressively-shortened"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013313","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}